Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with a specific type of aggressive lymphoma called DLBCL (Diffuse Large B-Cell Lymphoma) that is at a limited (early) stage and is not considered "bulky" (very large), confirmed using standard lymphoma staging tests including a PET scan and bone marrow biopsy
- People diagnosed with grade 3B follicular lymphoma or a slow-growing lymphoma that has transformed into a more aggressive type are also included
- People aged 18 or older
- People whose lymphoma can be measured and detected on a PET scan
- People who have tumor tissue samples available — either stored from a previous biopsy or collected fresh
- People who do not have other serious, uncontrolled health conditions
- People whose heart is functioning well enough (the heart's pumping strength must be at least 50%) and who do not have unstable chest pain (unstable angina)
- People whose kidneys are working well enough (confirmed by a kidney function test)
- People whose liver is working well enough (liver blood test results must be within an acceptable range, with a specific allowance for people who have a condition called Gilbert's disease)
- People whose blood cell counts are at acceptable levels, as determined by the treating doctor
Who may not be able to join:
- People who are pregnant, breastfeeding, or who have had a positive pregnancy blood test within 28 days before enrolling
- People whose lymphoma tumours are larger than 10 cm in any direction (considered "bulky" disease)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Carla Casulo, University of Rochester
Phone: 585-273-1507
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Correlation between fluorodeoxyglucose positron emission tomography (FDG-PET) and MRD, as measured by circulating tumor plasma DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.